Drawing more attention to bleeding disorders in women

Article

Clinicians need to be more aware of the presenceof specific bleeding disorders and develop strategies for correctly diagnosing the 2.5 million American women with abnormal bleeding who are at risk for unnecessary hysterectomies.

That's the message being spread by leading hematologists and ob/gyns who recently met in Seattle for the first-ever conference on women's bleeding disorders. Sponsored by the National Hemophilia Foundation, the Centers for Disease Control and Prevention, and ZLB-Behring, the purpose of the conference was to counter the lack of information and awareness about women's bleeding disorders. The conference, titled "Project Red Flag: Real Talk About Women's Bleeding Disorders," is part of an ongoing effort to identify where the greatest gaps in knowledge exist. A recent survey found, for example, that despite the fact that about one third of women report having "heavy" periods—the number one symptom of von Willebrand disease—most women (91%) have never heard of VWD.

National Hemophilia Foundation. Real talk about women's bleeding disorders: Getting women and their doctors to listen. www.hemophilia.org/News/prfnews/prf_05_13-04.htm .

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
© 2024 MJH Life Sciences

All rights reserved.